Harmony Biosciences Holdings (HRMY) Cash & Current Investments (2019 - 2026)

Harmony Biosciences Holdings has disclosed Cash & Current Investments across 8 years of filings, most recently posting $640.9 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $640.9 million, up 45.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $640.9 million (up 45.22% YoY), and the FY2025 annual result was $775.3 million, up 65.96% from the prior year.
• Cash & Current Investments came in at $640.9 million for Q1 2026 at Harmony Biosciences Holdings, down from $775.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $775.3 million in Q4 2025 to a low of $224.5 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $372.3 million (2024), against an average of $428.8 million.
• Across the five-year window, Cash & Current Investments jumped 133.58% in 2022 and declined 13.54% in 2024, its largest moves.
• Harmony Biosciences Holdings' Cash & Current Investments stood at $366.2 million in 2022, then dropped by 3.48% to $353.5 million in 2023, then soared by 32.18% to $467.2 million in 2024, then jumped by 65.96% to $775.3 million in 2025, then slipped by 17.34% to $640.9 million in 2026.
• The last three Cash & Current Investments figures came in at $640.9 million (Q1 2026), $775.3 million (Q4 2025), and $672.6 million (Q3 2025), per Business Quant data.